vs
AMERICAN REALTY INVESTORS INC（ARL）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是AMERICAN REALTY INVESTORS INC的1.5倍（$19.6M vs $13.0M），AMERICAN REALTY INVESTORS INC净利率更高（75.2% vs -177.4%，领先252.6%），AMERICAN REALTY INVESTORS INC同比增速更快（8.1% vs -11.5%），过去两年AMERICAN REALTY INVESTORS INC的营收复合增速更高（4.6% vs -12.2%）
原温加顿地产投资者是一家房地产投资信托公司，主要投资于美国南部的购物中心，且项目大多以杂货店作为主力店。该公司在2021年8月被金考地产收购。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
ARL vs LAB — 直观对比
营收规模更大
LAB
是对方的1.5倍
$13.0M
营收增速更快
ARL
高出19.5%
-11.5%
净利率更高
ARL
高出252.6%
-177.4%
两年增速更快
ARL
近两年复合增速
-12.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $13.0M | $19.6M |
| 净利润 | $9.8M | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | -23.3% | -168.5% |
| 净利率 | 75.2% | -177.4% |
| 营收同比 | 8.1% | -11.5% |
| 净利润同比 | 6175.8% | -28.8% |
| 每股收益（稀释后） | $0.60 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARLLAB
| Q4 25 | $13.0M | — | ||
| Q3 25 | $12.8M | $19.6M | ||
| Q2 25 | $12.2M | $21.8M | ||
| Q1 25 | $12.0M | $40.8M | ||
| Q4 24 | $12.0M | — | ||
| Q3 24 | $11.6M | $22.1M | ||
| Q2 24 | $11.8M | $22.5M | ||
| Q1 24 | $11.9M | $45.5M |
净利润ARLLAB
| Q4 25 | $9.8M | — | ||
| Q3 25 | $129.0K | $-34.7M | ||
| Q2 25 | $2.8M | $-33.5M | ||
| Q1 25 | $3.0M | $-26.0M | ||
| Q4 24 | $-161.0K | — | ||
| Q3 24 | $-17.5M | $-26.9M | ||
| Q2 24 | $1.2M | $-45.7M | ||
| Q1 24 | $1.8M | $-32.2M |
毛利率ARLLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% | ||
| Q1 24 | — | 53.1% |
营业利润率ARLLAB
| Q4 25 | -23.3% | — | ||
| Q3 25 | -12.3% | -168.5% | ||
| Q2 25 | -8.3% | -118.1% | ||
| Q1 25 | -6.8% | -80.8% | ||
| Q4 24 | -14.8% | — | ||
| Q3 24 | -17.8% | -120.9% | ||
| Q2 24 | -10.8% | -134.5% | ||
| Q1 24 | -12.7% | -132.2% |
净利率ARLLAB
| Q4 25 | 75.2% | — | ||
| Q3 25 | 1.0% | -177.4% | ||
| Q2 25 | 23.2% | -153.7% | ||
| Q1 25 | 24.7% | -63.8% | ||
| Q4 24 | -1.3% | — | ||
| Q3 24 | -150.4% | -122.0% | ||
| Q2 24 | 9.9% | -203.3% | ||
| Q1 24 | 14.7% | -70.6% |
每股收益（稀释后）ARLLAB
| Q4 25 | $0.60 | — | ||
| Q3 25 | $0.01 | $-0.09 | ||
| Q2 25 | $0.18 | $-0.09 | ||
| Q1 25 | $0.18 | $-0.07 | ||
| Q4 24 | $-0.01 | — | ||
| Q3 24 | $-1.08 | $-0.07 | ||
| Q2 24 | $0.07 | $-0.12 | ||
| Q1 24 | $0.11 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.1M | $129.4M |
| 总债务越低越好 | $214.4M | — |
| 股东权益账面价值 | $617.4M | $399.7M |
| 总资产 | $1.1B | $539.6M |
| 负债/权益比越低杠杆越低 | 0.35× | — |
8季度趋势，按日历期对齐
现金及短期投资ARLLAB
| Q4 25 | $89.1M | — | ||
| Q3 25 | $82.8M | $129.4M | ||
| Q2 25 | $73.5M | $158.6M | ||
| Q1 25 | $88.7M | $150.9M | ||
| Q4 24 | $99.7M | — | ||
| Q3 24 | $131.6M | $210.6M | ||
| Q2 24 | $127.5M | $269.8M | ||
| Q1 24 | $130.9M | $287.1M |
总债务ARLLAB
| Q4 25 | $214.4M | — | ||
| Q3 25 | $227.0M | — | ||
| Q2 25 | $216.0M | — | ||
| Q1 25 | $201.7M | — | ||
| Q4 24 | $185.4M | — | ||
| Q3 24 | $183.8M | $55.2M | ||
| Q2 24 | $181.0M | $55.1M | ||
| Q1 24 | $181.8M | $55.0M |
股东权益ARLLAB
| Q4 25 | $617.4M | — | ||
| Q3 25 | $607.8M | $399.7M | ||
| Q2 25 | $607.8M | $424.5M | ||
| Q1 25 | $604.9M | $454.6M | ||
| Q4 24 | $601.8M | — | ||
| Q3 24 | $602.2M | $489.3M | ||
| Q2 24 | $619.9M | $510.3M | ||
| Q1 24 | $618.8M | $577.3M |
总资产ARLLAB
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | $539.6M | ||
| Q2 25 | $1.1B | $557.0M | ||
| Q1 25 | $1.0B | $579.6M | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | $681.5M | ||
| Q2 24 | $1.0B | $708.7M | ||
| Q1 24 | $1.0B | $777.7M |
负债/权益比ARLLAB
| Q4 25 | 0.35× | — | ||
| Q3 25 | 0.37× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.33× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.31× | 0.11× | ||
| Q2 24 | 0.29× | 0.11× | ||
| Q1 24 | 0.29× | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.6M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-23.1M |
| 自由现金流率自由现金流/营收 | — | -118.1% |
| 资本支出强度资本支出/营收 | — | 4.5% |
| 现金转化率经营现金流/净利润 | -0.57× | — |
| 过去12个月自由现金流最近4个季度 | — | $-111.1M |
8季度趋势，按日历期对齐
经营现金流ARLLAB
| Q4 25 | $-5.6M | — | ||
| Q3 25 | $8.0M | $-22.2M | ||
| Q2 25 | $-2.9M | $-20.7M | ||
| Q1 25 | $-7.4M | $-30.3M | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $13.5M | $-27.9M | ||
| Q2 24 | $-503.0K | $-39.0M | ||
| Q1 24 | $3.9M | $-62.5M |
自由现金流ARLLAB
| Q4 25 | — | — | ||
| Q3 25 | — | $-23.1M | ||
| Q2 25 | — | $-22.6M | ||
| Q1 25 | — | $-35.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-30.1M | ||
| Q2 24 | — | $-41.0M | ||
| Q1 24 | — | $-63.3M |
自由现金流率ARLLAB
| Q4 25 | — | — | ||
| Q3 25 | — | -118.1% | ||
| Q2 25 | — | -103.6% | ||
| Q1 25 | — | -86.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -136.4% | ||
| Q2 24 | — | -182.2% | ||
| Q1 24 | — | -138.9% |
资本支出强度ARLLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 4.5% | ||
| Q2 25 | — | 8.7% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 10.2% | ||
| Q2 24 | — | 8.6% | ||
| Q1 24 | — | 1.7% |
现金转化率ARLLAB
| Q4 25 | -0.57× | — | ||
| Q3 25 | 61.81× | — | ||
| Q2 25 | -1.03× | — | ||
| Q1 25 | -2.50× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -0.43× | — | ||
| Q1 24 | 2.21× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARL
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
